Anti-Inflammatory Drugs Global Market Report 2025

The anti-inflammatory drugs market size has grown rapidly in recent years. It will grow from $136.86 billion in 2024 to $152.08 billion in 2025 at a compound annual growth rate (CAGR) of 11.1%. Growth during the historic period can be attributed to several key factors, including an aging population, the increasing prevalence of chronic inflammatory diseases, greater over-the-counter availability of medications, rising awareness of pain management, and the expansion of healthcare infrastructure.

The anti-inflammatory drugs market size is expected to see rapid growth in the next few years. It will grow to $228.83 billion in 2029 at a compound annual growth rate (CAGR) of 10.8%. Growth in the forecast period is expected to be driven by the rising incidence of autoimmune diseases, increasing demand for personalized medicine, a growing geriatric population, supportive government initiatives, and a rising preference for topical and targeted therapies. Key trends anticipated during this period include innovations in biologic drugs, a shift toward biologics and biosimilars, the rise of telemedicine-based prescriptions, the integration of artificial intelligence in drug discovery, ongoing research and development of novel anti-inflammatory mechanisms, and advancements in targeted anti-inflammatory therapies.

The increasing prevalence of arthritis is expected to drive the growth of the anti-inflammatory drugs market in the coming years. Arthritis is characterized by inflammation in one or more joints, leading to pain, swelling, and stiffness that often worsens with age. The growing incidence of arthritis is largely attributed to aging populations, as the natural wear and tear on joints over time raises the risk of developing the condition. Anti-inflammatory drugs play a key role in managing arthritis by reducing joint inflammation and pain, helping patients maintain mobility, perform daily activities more comfortably, and improve their overall quality of life. For example, in March 2023, the Office for Health Improvement and Disparities, a UK government department, reported that in 2022, 17.6% of individuals aged 16 and above had a long-term musculoskeletal (MSK) condition - such as arthritis or persistent joint or back issues - an increase from 17% in 2021. Thus, the rising prevalence of arthritis is contributing significantly to the growth of the anti-inflammatory drugs market.

Leading companies in the anti-inflammatory drugs market are focusing on developing innovative formulations, such as topical solutions, to improve targeted drug delivery and enhance patient compliance. A topical solution is a liquid form of medication applied directly to the skin or affected area, allowing the active ingredients to act locally at the site of inflammation while minimizing systemic side effects. For example, in December 2022, Lupin Limited, an India-based pharmaceutical company, launched the authorized generic version of PENNSAID (Diclofenac Sodium Topical Solution, 2% w/w) from Horizon Pharma Therapeutics in the United States. This move aimed to expand Lupin’s U.S. generics portfolio and improve access to affordable anti-inflammatory treatments. The drug, a nonsteroidal anti-inflammatory agent, is used to relieve pain caused by osteoarthritis of the knee, offering localized relief through topical application and reducing the systemic risks associated with oral NSAIDs.

In March 2022, Pfizer, a U.S.-based pharmaceutical company, acquired Arena Pharmaceuticals for approximately $6.7 billion. This acquisition was intended to strengthen Pfizer’s pipeline of potential therapies targeting immuno-inflammatory diseases, with a focus on areas such as gastroenterology, dermatology, and cardiology. Arena Pharmaceuticals, also based in the U.S., is a clinical-stage company dedicated to developing innovative treatments for a range of immuno-inflammatory conditions.

Major players in the anti-inflammatory drugs market are Merck & Co. Inc., AbbVie Inc., Bayer AG, Novartis AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca plc, Gilead Sciences Inc., Amgen Inc., Regeneron Pharmaceuticals Inc., Biogen Inc., Vertex Pharmaceuticals Inc., UCB S.A., Sun Pharmaceutical Industries Ltd., Aurobindo Pharma Limited, Dr. Reddy’s Laboratories, Cipla Limited, Cadila Pharmaceuticals, Samsung Bioepis, Lupin Limited.

North America was the largest region in the anti-inflammatory drugs market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in anti-inflammatory drugs report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the anti-inflammatory drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Anti-inflammatory drugs are a category of medications designed to alleviate inflammation, pain, fever, and swelling by disrupting the body’s natural inflammatory processes. They function by blocking the activity or production of chemical messengers like prostaglandins, leukotrienes, and cytokines, which play key roles in initiating and maintaining inflammation.

The primary classes of anti-inflammatory drugs include steroids, nonsteroidal anti-inflammatory drugs (NSAIDs), biologics and biosimilars, among others. Steroids, which imitate natural hormones, are commonly used to manage conditions such as asthma, arthritis, and allergies. These medications can be administered in various forms, including parenteral, oral, topical, and inhalation routes. They are employed in the treatment of multiple conditions, including autoimmune and respiratory diseases. Anti-inflammatory drugs are distributed through several channels, including hospital pharmacies, retail pharmacies, and online pharmacies.

The anti-inflammatory drugs market research report is one of a series of new reports that provides anti-inflammatory drugs market statistics, including anti-inflammatory drugs industry global market size, regional shares, competitors with the anti-inflammatory drugs market share, anti-inflammatory drugs market segments, market trends, and opportunities, and any further data you may need to thrive in the anti-inflammatory drugs industry. This anti-inflammatory drug market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The anti-inflammatory drugs market consists of sales of immunosuppressants, COX-2 inhibitors, interleukin inhibitors, and TNF-alpha inhibitors. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.